| Ilse Violeta Vargas Catindig, OTRL | |
|
3801 Miranda Ave, Palo Alto, CA 94304-1207 | |
| (650) 493-5000 | |
| Not Available |
| Full Name | Ilse Violeta Vargas Catindig |
|---|---|
| Gender | Female |
| Speciality | Occupational Therapist - Neurorehabilitation |
| Location | 3801 Miranda Ave, Palo Alto, California |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1144320953 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 225XN1300X | Occupational Therapist - Neurorehabilitation | OT 8914 (California) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Ilse Violeta Vargas Catindig, OTRL 1275 French Ct, Milpitas, CA 95035-6990 Ph: (408) 480-3687 | Ilse Violeta Vargas Catindig, OTRL 3801 Miranda Ave, Palo Alto, CA 94304-1207 Ph: (650) 493-5000 |
News Archive
Palatin Technologies, Inc. today reported positive top-line results, including the successful achievement of statistical significance for the primary endpoint and key secondary endpoints in its Phase 2B clinical trial evaluating the efficacy and safety of bremelanotide for the treatment of female sexual dysfunction (FSD).
Minnesota hospitals and health systems have prevented more than 12,000 patients from being harmed and saved more than $93 million as a result of a reduction in hospital-acquired conditions from 2010-13. Nationwide, hospitals prevented 1.3 million patient harms and saved more than $12 billion in health spending, according to a report issued today by the U.S. Department of Health and Human Services.
The fatality rate among infected people increases among the elderly and those with underlying medical conditions. Now, a new study published as a pre-print on medXriv, links smoking to the progression of COVID-19 disease, suggesting that the odds of disease progression is more than double in smokers.
QRxPharma Limited announced today initiation of the New Drug Application (NDA) approval process for MoxDuo IR with the United States Food and Drug Administration (FDA). This NDA submission sets the stage for the regulatory approval process for MoxDuo IR for the treatment of moderate to severe acute pain, a $2.5 billion segment of the $8 billion spent annually on prescription opioids in the US.
› Verified 4 days ago
Eiri Inenaga, MS, OTR/L Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 725 Welch Rd, Palo Alto, CA 94304 Phone: 650-497-8218 | |
Kristi Lynne O'connor, OT Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 725 Welch Rd, Palo Alto, CA 94304 Phone: 650-497-8000 | |
Mrs. Jean Jones Gurga, OTR/L Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 3801 Miranda Ave, Pmrs (117), Palo Alto, CA 94304 Phone: 650-493-5000 | |
Anna Narem, OTR/L Occupational Therapist Medicare: Medicare Enrolled Practice Location: 911 Bryant St, Palo Alto, CA 94301 Phone: 650-327-0511 | |
Brenda Pritts, OTR/L Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 257 Mosher Way, Palo Alto, CA 94304 Phone: 614-893-5159 | |
Yu-chun Su, Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 620 Sand Hill Rd, Palo Alto, CA 94304 Phone: 888-926-1850 | |
Jill Storms, Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 3801 Miranda Ave, Palo Alto, CA 94304 Phone: 650-493-5000 |